Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (211-220 of 388) with videos related to

Pageof 39
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|January 7, 2015
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatmentFrancesca V Negri, Barbara Dal Bello, Camillo Porta, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumorsBarbara Mandriani, Eleonora Pellè, Francesco Mannavola, et al.
Oncology Research|May 1, 2026
The Real-World Endocrine Toxicity Profile of ICIs, VEGFR-TKIs, and Their Combination: Analysis of the FDA Adverse Event Reporting System (FAERS) DatabaseNicola Marrano, Mariangela Caporusso, Cosimo Matino, et al.
European Urology|September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell CarcinomaSumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.
BMC Cancer|September 8, 2009
Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term resultsGiulia Bertino, Antonio Occhini, Carlo Emilio Falco, et al.
International Journal of Oncology|July 2, 2011
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trialLaura Ridolfi, Oscar Bertetto, Antonio Santo, et al.
Journal of Neuroendocrinology|October 1, 2021
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerabilityEleonora Lauricella, Mauro Cives, Alessandra Bracigliano, et al.
Virchows Archiv : an International Journal of Pathology|April 29, 2023
STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinomaStefano Marletta, Anna Caliò, Giuseppe Bogina, et al.
Oncology|June 9, 2012
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinomaFrank Stenner, Rahel Chastonay, Heike Liewen, et al.
European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.
Pageof 39

Showing results (211-220 of 388) with videos related to

Sort By:
Pageof 39
Liver International : Official Journal of the International Association for the Study of the Liver|January 7, 2015
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatmentFrancesca V Negri, Barbara Dal Bello, Camillo Porta, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumorsBarbara Mandriani, Eleonora Pellè, Francesco Mannavola, et al.
Oncology Research|May 1, 2026
The Real-World Endocrine Toxicity Profile of ICIs, VEGFR-TKIs, and Their Combination: Analysis of the FDA Adverse Event Reporting System (FAERS) DatabaseNicola Marrano, Mariangela Caporusso, Cosimo Matino, et al.
European Urology|September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell CarcinomaSumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.
BMC Cancer|September 8, 2009
Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term resultsGiulia Bertino, Antonio Occhini, Carlo Emilio Falco, et al.
International Journal of Oncology|July 2, 2011
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trialLaura Ridolfi, Oscar Bertetto, Antonio Santo, et al.
Journal of Neuroendocrinology|October 1, 2021
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerabilityEleonora Lauricella, Mauro Cives, Alessandra Bracigliano, et al.
Virchows Archiv : an International Journal of Pathology|April 29, 2023
STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinomaStefano Marletta, Anna Caliò, Giuseppe Bogina, et al.
Oncology|June 9, 2012
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinomaFrank Stenner, Rahel Chastonay, Heike Liewen, et al.
European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.
Pageof 39